Astria Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

-- FDA Cleared IND Application for STAR-0215 for the Treatment of Hereditary Angioedema ---- Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects Initiated, Preliminary Results Anticipated by Year-End 2022 ---- Company to Host a Virtual R&D Day on September 30 --BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc....

Related Keywords

Jillc Milne ,Instagram Astriatx ,Andrea Matthews ,Chris Morabito ,Linkedin ,Neither The Company ,Twitter ,Drug Administration ,Astria Therapeutics Inc ,Nasdaq ,Facebook ,Clinical Development For The Prevention ,European Academy Of Allergy ,Clinical Trial ,Healthy Subjects Initiated ,Preliminary Results Anticipated ,Virtual Rd Day ,Astria Therapeutics ,Chief Executive Officer ,Investigational New Drug ,Igg Targeted Therapies Conference ,European Academy ,Clinical Immunology ,Chief Medical ,Clinical Development ,Loss Per Share Basic ,Annual Report ,Months Ended June ,Consolidated Statements ,Cash Flows ,